Lycia Therapeutics (LYCA) Jumps After IPO With Valuation Questions Now Front And Center
Lycia Therapeutics surges in debut following upsized $317.5M IPO
Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
